Longeveron Welcomes Than Powell as Chief Business Officer
Significant Leadership Change at Longeveron
MIAMI — In a strategic move, Longeveron Inc. (NASDAQ: LGVN), a biotechnology firm focused on regenerative medicine, has appointed Than Powell as its new Chief Business Officer. This announcement marks a pivotal moment in Longeveron’s journey as they pioneer innovative therapies for serious conditions associated with aging and other chronic diseases.
A Leader in Business Strategy
Effective July 7, 2025, Than Powell will be at the forefront of Longeveron’s business strategy, specifically focusing on navigating the complex landscape of partnerships, particularly regarding Alzheimer's disease. Additionally, he will steer the international strategy for the hypoplastic left heart syndrome (HLHS) program, showcasing his extensive background in the pharmaceutical and biotechnology sectors.
Transformative Period for the Company
“We are thrilled to welcome Than aboard during this transformative phase for Longeveron,” expressed Wa’el Hashad, the CEO of the company. With the recent milestone of enrolling participants in a pivotal Phase 2 trial assessing laromestorcel, a stem cell therapy for HLHS, Longeveron is on the brink of reviewing pivotal data. This positive outcome may lead the way for the firm's first Biological License Application (BLA) submission, a significant achievement in the biopharmaceutical arena.
Than Powell’s Impressive Background
Than Powell brings over 25 years of invaluable experience to Longeveron, having held various leadership roles in established pharmaceutical firms, including GSK and Eli Lilly. His previous position as head of Corporate Development & Strategy at Surescripts culminated in the company's acquisition by TPG, highlighting his knack for driving corporate growth.
Commitment to Longeveron’s Mission
“I am honored to join Longeveron,” Powell remarked about his new position. “The innovative spirit and commitment to scientific excellence at Longeveron resonate with me, especially given my family's personal experiences with diseases currently under study. I look forward to advancing the company's mission and aiding patients through potential stem cell therapy approvals.”
About Longeveron Inc.
Longeveron stands at the cutting edge of regenerative medicine, dedicated to developing groundbreaking therapies to address unmet medical needs. Their flagship investigational product, laromestrocel (Lomecel-B™), is designed to leverage the regenerative capabilities of stem cells derived from the bone marrow of healthy, young donors. This innovative therapy holds promise across various disease areas due to its multiple mechanisms, including pro-vascular and anti-inflammatory effects.
Significant FDA Designations
Currently, Longeveron is engaged in three crucial pipeline indications, namely HLHS, Alzheimer’s disease, and Aging-related Frailty. With recognition from the FDA, laromestrocel has received notable designations like Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation for HLHS. Furthermore, its Alzheimer’s program also benefits from the Regenerative Medicine Advanced Therapy (RMAT) designation, supporting its expedited development.
Contact Information
For further inquiries, interested parties can reach out to Derek Cole at Investor Relations Advisory Solutions via email at derek.cole@iradvisory.com. Longeveron invites those eager to learn more about their innovative endeavors to visit their official website and stay updated through their social media channels.
Frequently Asked Questions
What role will Than Powell serve at Longeveron?
Than Powell will function as the Chief Business Officer, overseeing the company's business strategy and global initiatives.
What is laromestrocel?
Laromestrocel (Lomecel-B™) is a stem cell therapy aimed at addressing various health conditions, especially those related to aging and chronic diseases.
What sectors will Longeveron focus on with Powell's leadership?
Under Powell’s guidance, Longeveron will enhance its efforts in Alzheimer's disease and develop international strategies for its HLHS program.
How long has Than Powell been in the pharmaceutical industry?
Than Powell has over 25 years of experience across various significant organizations in the pharmaceutical and biotech sectors.
What are the FDA designations Longeveron has received?
Longeveron’s laromestrocel has garnered multiple FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease for HLHS.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.